Correlates of Protection and Determinants of SARS-CoV-2 Breakthrough Infections 1 Year After Third Dose Vaccination

Scientists evaluated antibody responses to SARS-CoV-2 spike and nucleocapsid antigens from Wuhan and variants of concern by Luminex and their role in preventing breakthrough infections 1 year after a third dose of mRNA vaccination, in a cohort of health care workers followed since the pandemic onset in Spain.